1.
Targeting cellular senescence prevents age-related bone loss in mice
by Farr, Joshua N
Nature medicine, 2017-09, Vol.23 (9), p.1072-1079
2.
Targeting skeletal endothelium to ameliorate bone loss
by Xu, Ren
Nature medicine, 2018-06, Vol.24 (6), p.823-833
3.
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
by Xian, Lingling
Nature medicine, 2012-07, Vol.18 (7), p.1095-1101
4.
Trabecular Bone Score (TBS)—A Novel Method to Evaluate Bone Microarchitectural Texture in Patients With Primary Hyperparathyroidism
by Silva, Barbara Campolina
The journal of clinical endocrinology and metabolism, 2013-05, Vol.98 (5), p.1963-1970
5.
Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome
by Sakka, Sophia
The journal of clinical endocrinology and metabolism, 2017-11, Vol.102 (11), p.4163-4172
6.
Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice
by Xiao, Liping
Endocrinology (Philadelphia), 2017-10-01, Vol.158 (10), p.3629-3646
7.
Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors
by Nohr, Erik
Human pathology, 2017-10, Vol.68, p.119-127
8.
Insights into Material and Structural Basis of Bone Fragility from Diseases Associated with Fractures: How Determinants of the Biomechanical Properties of Bone Are Compromised by D...
by Chavassieux, P
Endocrine reviews, 2007-04, Vol.28 (2), p.151-164
9.
Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?
by Lalayiannis, A.D
Pediatric nephrology (Berlin, West), 2019-06-25, Vol.35 (6), p.937-957
10.
Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats
by Li, Xiaodong
Endocrinology (Philadelphia), 2011-09, Vol.152 (9), p.3312-3322
11.
Effects of reproduction on sexual dimorphisms in rat bone mechanics
by de Bakker, Chantal M.J
Journal of biomechanics, 2018-08-22, Vol.77, p.40-47
12.
Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone
by Rutkowski, Piotr
Annals of surgical oncology, 2015-06-02, Vol.22 (9), p.2860-2868
13.
Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect
by Ortuño, María José
Nature medicine, 2016-10, Vol.22 (10), p.1170-1179
14.
Matrix-embedded cells control osteoclast formation
by Xiong, Jinhu
Nature medicine, 2011-09-11, Vol.17 (10), p.1235-1241
15.
Bone Metabolism in Obesity and Weight Loss
by SHAPSES, Sue A
Annual review of nutrition, 2012, Vol.32 (1), p.287-309
16.
Diabetes, bone and glucose-lowering agents: basic biology
by Lecka-Czernik, Beata
Diabetologia, 2017-04-22, Vol.60 (7), p.1163-1169
17.
Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report
by Lamy, Olivier
The journal of clinical endocrinology and metabolism, 2017-02, Vol.102 (2), p.354-358
18.
Bone impairment in primary hyperoxaluria: a review
by Bacchetta, Justine
Pediatric Nephrology, 2015-01-29, Vol.31 (1), p.1-6
19.
The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management
by Felsenberg, Dieter
Clinical therapeutics, 2005, Vol.27 (1), p.1-11
20.
Attenuated BMP1 Function Compromises Osteogenesis, Leading to Bone Fragility in Humans and Zebrafish
by Asharani, P.V
American journal of human genetics, 2012-04-06, Vol.90 (4), p.661-674
